Bristol Myers Squibb

 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Retrieved on: 
Saturday, April 6, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, BMY, Circulatory system, Head, Xerostomia, SIRS, Schizophrenia, Xanomeline, Dizziness, Glycated hemoglobin, Extrapyramidal symptoms, Weight gain, Patient, Syndrome, Constipation, Diarrhea, Bristol Myers Squibb, MD, Nature, Congress, Indigestion, Nausea, Prolactin, Safety, Vomiting, BMI, Schizophrenia International Research Society, Hypertension, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.
  • “These long-term safety results and metabolic outcomes from the EMERGENT program are extremely encouraging, allowing us to further understand the tolerability profile of KarXT in people living with schizophrenia,” said Roland Chen , MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb.
  • In the pooled analysis, KarXT demonstrated a favorable impact on weight and long-term metabolic profile where most patients experienced stability or improvements on key metabolic parameters over 52 weeks of treatment.
  • In the long-term studies, KarXT was generally well-tolerated across 52 weeks of treatment, with a side effect profile consistent with prior trials of KarXT in schizophrenia.

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Retrieved on: 
Saturday, April 6, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, BMY, Circulatory system, Head, SIRS, Schizophrenia, Xanomeline, Assessment, Patient, Bristol Myers Squibb, MD, Positive, Efficacy, Congress, Prolactin, Clinical trial, Safety, PANSS, FDA, Schizophrenia International Research Society, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia.
  • Long-term efficacy data from the trial were presented in a poster titled, “Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia” (Poster F264) at the Annual Congress of the Schizophrenia International Research Society (SIRS) being held April 3-7, 2024, in Florence, Italy.
  • In the interim analysis, KarXT was associated with significant improvement in symptoms of schizophrenia across all efficacy measures at 52 weeks.
  • In long-term trials, KarXT was generally well tolerated, with a side effect profile consistent with prior trials of KarXT in schizophrenia.

2024 Oncology Nurse Advisor Summit Shatters Attendance Records

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Nursing, Education, Health, Continuing, Training, Diagnosis, RN, MHA, Inclusion, NACE, CPPS, Faculty, NSCLC, Real, ONA, American Cancer Society, Knowledge, DNP, Accreditation, Oncology nursing, AANP, Merck, Fox Chase Cancer Center, Bristol Myers Squibb, Oncology Nursing Certification Corporation, MSN, ANCC, Johnson & Johnson, Merck & Co., Summit, National Association, Hematology, Skin cancer, HMN, HME

Over 2,200 attendees enriched their knowledge in disease-specific and supportive care topics during the 9th Annual Oncology Nurse Advisor (ONA) Summit, which occurred from March 21-24, 2024.

Key Points: 
  • Over 2,200 attendees enriched their knowledge in disease-specific and supportive care topics during the 9th Annual Oncology Nurse Advisor (ONA) Summit, which occurred from March 21-24, 2024.
  • New to the 2024 Summit was a one-day pre-conference Hematology Intensive on March 21 titled, What’s Blood Got to Do With It?
  • Also new to the Summit was the Real Solutions Virtual Poster Gallery, which presented real-life, innovative strategies and quality improvement solutions submitted by oncology nurses, which were selected for the Summit through a blind review by ONA Summit course directors.
  • Paula Anastasia, MN, RN, AOCN®, GYN Oncology Clinical Nurse Specialist, UCLA Health Sciences, participated in the Summit as Clinical Advisor, Peer Reviewer and Expert Moderator.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Janus, Growth, Novo Holdings A/S, NSCLC, TIL, Patient, Wellington Management Company, Paradigm, Foresite Capital, Bristol Myers Squibb, Lung cancer, Doctor of Philosophy, Therapy, Melanoma, Investment, Atlas Venture, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
  • Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
  • The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
  • “This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Retrieved on: 
Friday, April 5, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, BMY, Disease, Progression-free survival, Patient, Research, Multiple myeloma, Pi, Commercial, Bristol Myers Squibb, Cytokine release syndrome, Idecabtagene vicleucel, Multimedia, Immunotherapy, Immunomodulatory imide drug, Food, Pharmaceutical industry

This approval expands Abecma’s indication, making it available in earlier lines to patients who have relapsed or become refractory after exposure to these three main classes of treatment (triple-class exposed), after two prior lines of therapy.

Key Points: 
  • This approval expands Abecma’s indication, making it available in earlier lines to patients who have relapsed or become refractory after exposure to these three main classes of treatment (triple-class exposed), after two prior lines of therapy.
  • Abecma was recently approved in Japan, Switzerland and the European Union for adult patients with triple-class exposed relapsed and/or refractory multiple myeloma after two prior lines of therapy, making it the only CAR T cell therapy available globally for earlier lines of therapy for patients with triple-class exposed relapsed and/or refractory multiple myeloma.
  • Abecma is also currently approved in Great Britain and Israel for adult patients with triple-class exposed relapsed and refractory multiple myeloma after three or more prior lines of therapy.
  • KarMMa-3 is the only Phase 3 trial to evaluate a CAR T cell therapy in a patient population consisting entirely of triple-class exposed relapsed and refractory multiple myeloma patients.

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Philanthropy, Pharmaceutical, Sustainability, DEI (Diversity, Equity and Inclusion), Environment, Clinical Trials, Biotechnology, Human Resources, Climate Change, Other Philanthropy, Health, Environmental, Social and Governance (ESG), Electricity, BMY, Multiple myeloma, Science, Health equity, ESG, Patient, VPPA, Ethics, Pulmonary fibrosis, Research, Climate, Female, Artificial intelligence, BMS, Bristol Myers Squibb, Doctor of Philosophy, Clinical trial, Task force, TCFD, Lupus, Patient safety, Workforce, Chairperson, Improvement, Multimedia, Privacy, Targets, Developing country, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.
  • The company’s ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
  • View the full release here: https://www.businesswire.com/news/home/20240402638203/en/
    “For more than 130 years, BMS has enabled positive change for our patients around the world.
  • Incorporated new ESG metrics into the executive compensation program, measuring achievement against environmental and social goals and better aligning executive bonuses with company strategy.

Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, MSD, Ovarian cancer, Mirati Therapeutics, London Business School, University of Coimbra, GSK, BMS, Doctor of Philosophy, Therapy, Algeta, Colorectal cancer, International, Pharmacy, Radiopharmaceutical, Radium-223, Agios Pharmaceuticals, Amgen, Cubist Pharmaceuticals, Takeda Pharmaceutical Company, Bristol Myers Squibb, University, Private sector, The central science, Drug development, Sanofi, Psychiatry, BASF, Master of Science, M.B.A, Science, GE HealthCare, Pharmaceutical industry

“We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.

Key Points: 
  • “We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.
  • “We are also pleased to announce the formation of a Scientific and Clinical Advisory Board, consisting of our highly distinguished founders who are uniquely positioned to support Oncoinvent in our clinical programs.
  • Dr. O’Bryan-Tear has been an adviser to several US and European biotech companies and has held board positions at Fusion Pharmaceuticals and Clarity Pharmaceuticals.
  • In addition, Oncoinvent founding scientists Roy Larsen, Ph.D., and Øyvind Bruland, M.D., Ph.D., previously board members, will lead a newly established Scientific and Clinical Advisory Board.

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Civil service commission, BMY, Safety, Patient, Transfusion-dependent anemia, Bristol Myers Squibb, European Commission, Anemia, MDS, Epoetin alfa, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has expanded approval of Reblozyl® (luspatercept) to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has expanded approval of Reblozyl® (luspatercept) to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).
  • This approval of Reblozyl covers all EU member states.
  • Safety results were consistent with previous MDS studies and were in line with expected symptoms in this patient population.
  • Reblozyl is also approved in the United States and Japan for the first-line treatment of anemia associated with lower-risk MDS.

Mosaic Biosciences Expands Its Leading Drug Discovery and Development Expertise

Retrieved on: 
Tuesday, April 2, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biogen, Obesity, Drug discovery, Cancer immunotherapy, Diabetes, Malavi, History, BMS, Doctor of Philosophy, Bristol Myers Squibb, CTI, Therapy, Genomics, NASH, GNF, CSO, Antibody, Inflation, Autoimmunity, DSM-IV codes, Pharmaceutical industry

Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.

Key Points: 
  • Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.
  • Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
  • “I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice for discovering innovative protein therapeutics in a disease agnostic manner,” said Malavi.
  • “Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics,” said Scott.

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, LVV, BCMA, Patient, Sale, Multiple myeloma, BMS, Cancer, Bristol Myers Squibb, APA, Pharmaceutical industry

(Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc.

Key Points: 
  • (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc.
  • Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.
  • “With the completion of the Regeneron transaction, 2seventy officially embarks on our new strategic path forward to focus on unlocking the value of Abecma,” said Chip Baird, CEO.
  • With the resulting cost savings from reduced headcount and the sale of the pipeline assets to Regeneron, 2seventy bio has extended cash runway beyond 2027.